-- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening --
SAN FRANCISCO, June 17, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS).
"Since we began, Invitae has invested deeply to harness the power of the most advanced genetic testing technologies in order to deliver expert-level genetic information at scale, and bringing this company into Invitae is the next step in that process," said Sean George, PhD, co-founder and chief executive officer of Invitae. "Singular Bio is building an approach to non-invasive prenatal screening with the potential to achieve the cost savings necessary to provide more women with genetic information to support a healthy pregnancy. We believe this approach could eventually be applied to other areas of genetic testing. The addition of Singular Bio's technology will further strengthen our ability to bring genetic information into mainstream medical care."
Read More: https://www.prnewswire.com/news-releases/invitae-to-acquire-singular-bio-to-help-increase-access-to-genetic-screening-in-early-pregnancy-300869252.html
Via: PR Newswire
Vikram S Kashyap, co-principal investigator of the ROADSTER 2 trial, today presented the final 30-day outcomes of the post-market approval study in a late-breaking trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 12–15 June, National Harbor, USA). The data show the sustained safety and efficacy of transcarotid artery revascularisation (TCAR) with Silk Road Medical’s Enroute system. In this interview, Kashyap speaks to Vascular News about the procedure, and how TCAR trialists are hoping to make an impact for patients needing carotid revascularisation.
Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting
NATIONAL HARBOR, Md., June 13, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM). In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project.
Silk Road Medical Announces Key TCAR Presentations at the Society for Vascular Surgery 2019 Vascular Annual Meeting
SUNNYVALE, Calif. – June 4, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
For diabetic workers, access to a refrigerator and insulin breaks are not a workplace perk. They are potentially a matter of life and death.
Via: The Carle Foundation
The signs of Robert Nemeth’s mini-stroke were clear.
“I was standing in front of the refrigerator, and my right arm wouldn’t move. I realized something was very wrong,” Nemeth said.
The Sadorus man needed a procedure to help clear his carotid artery, which was 90 percent blocked. Because of previous radiation treatments to his neck, traditional surgery could have been risky.
Thankfully, surgeons at Carle Heart & Vascular Institute perform a minimally invasive procedure to reach the carotid artery through a small incision in the clavicle. Carle is the only Illinois hospital outside the Chicago and St. Louis areas to offer TransCarotid Artery Revascularization (TCAR).
“This is the future,” said Carle vascular surgeon Brian Beeman, MD. “TCAR is a much safer option for patients who are at high risk for traditional surgery, including patients with congestive heart failure and recent heart attack.”
Read More: https://newsroom.carle.org/quality-innovation/stroke-prevention-procedure-serves-as-option-for-high-risk-patients.htm
Gary Sunderland was recovering from a heart procedure at New Hanover Regional Medical Center when a physician assistant stopped by to assess him. Using a stethoscope, the physician assistant listened to the carotid artery in his neck.
Stealthy catheter developer Route 92 Medical, which is developing a catheter to treat stroke, last week said it raised nearly $13 million in an equity round.
SUNNYVALE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2019.